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A missense mutation in the MLKL brace region
promotes lethal neonatal inflammation and
hematopoietic dysfunction
Joanne M. Hildebrand et al.#
MLKL is the essential effector of necroptosis, a form of programmed lytic cell death. We have
isolated a mouse strain with a single missense mutation, MlklD139V, that alters the two-helix
‘brace’ that connects the killer four-helix bundle and regulatory pseudokinase domains. This
confers constitutive, RIPK3 independent killing activity to MLKL. Homozygous mutant mice
develop lethal postnatal inflammation of the salivary glands and mediastinum. The normal
embryonic development of MlklD139V homozygotes until birth, and the absence of any overt
phenotype in heterozygotes provides important in vivo precedent for the capacity of cells to
clear activated MLKL. These observations offer an important insight into the potential
disease-modulating roles of three common human MLKL polymorphisms that encode amino
acid substitutions within or adjacent to the brace region. Compound heterozygosity of these
variants is found at up to 12-fold the expected frequency in patients that suffer from a
pediatric autoinflammatory disease, chronic recurrent multifocal osteomyelitis (CRMO).
https://doi.org/10.1038/s41467-020-16819-z OPEN
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Necroptosis is a lytic form of programmed cell deathassociated with the production of pro-inflammatorycytokines, the destruction of biological membranes and
the release of intracellular damage associated molecular patterns
(DAMPs)1. Necroptosis depends on the activation of the mixed
lineage kinase domain-like (MLKL) pseudokinase by receptor
interacting protein kinase 3 (RIPK3)2–4. RIPK3-mediated phos-
phorylation of MLKL triggers a conformational change4,5 that
facilitates the translocation to, and eventual irreversible disrup-
tion of, cellular membranes. While the precise biophysical
mechanism of membrane disruption is still a matter of debate,
common features of contemporary models are the formation of
an MLKL oligomer and the direct association of the executioner
four-helix bundle domain (4HB) of MLKL with biological
membranes6–10. In mouse cells, the expression of the murine
MLKL 4HB domain alone (residues 1–125), 4HB plus brace
helices (1–180), or the expression of phosphomimetic or other
single site pseudokinase domain (PsKD) mutants is sufficient to
induce membrane translocation, oligomerization and membrane
destruction4,9. While capable of disrupting synthetic liposomes
when produced recombinantly, similarly truncated and equiva-
lent single site (PsKD) mutant forms of human MLKL do not
robustly induce membrane-associated oligomerization and cell
death without forced dimerization11–13. Furthermore, both
mouse and human MLKL mutants have been reported that have
the capacity to form membrane-associated oligomers, but fail to
cause irreversible membrane disruption and cell death9,13. Recent
studies have revealed that necroptosis downstream of MLKL
phosphorylation and membrane association can be modulated by
processes that engage the endosomal sorting complex required for
transport (ESCRT) family of proteins. One model proposes a role
for ESCRT in limiting necroptosis via plasma membrane excision
and repair14 while other models limit plasma membrane dis-
ruption by ESCRT-mediated release of phosphorylated MLKL in
extracellular vesicles15–17 and/or the internalization of phos-
phorylated MLKL for lysosomal degradation17.
In mice, the absence of MLKL does not appear to have obvious
deleterious developmental or homeostatic effects4,18. However,
genetic deletion of Fadd, Casp8 or Ripk1, leads to inappropriate
activation of MLKL and ensuing necroptosis during embry-
ogenesis that is incompatible with life beyond embryonic day (E)
10.5, E10.5 and 1–3 days post-natally, respectively19–25. Exploring
the precise physiological consequences of inappropriate MLKL
activation in these scenarios is complicated by the fact that
FADD, Caspase-8 and RIPK1 also play important roles in cellular
processes other than modulation of MLKL-induced necroptotic
cell death23,26–30.
Aberrant levels of MLKL-dependent cell death contribute to
disease in several genetic and experimental mouse models23,31–35.
In humans, MLKL mRNA and protein levels are positively cor-
related with survival of patients with pancreatic adenocarcinoma,
cervical-, gastric-, ovarian- and colon- cancers (reviewed by
ref. 36). Interestingly, high levels of phosphorylated MLKL are
associated with reduced survival in esophageal and colon cancer
patients37. Two missense MLKL somatic mutations identified in
human cancer tissue have been found to confer a reduction in
necroptotic function in cell-based assays4,13. Very recently, sib-
lings suffering from a novel neurodegenerative disorder were
reported as homozygous for a rare haplotype involving a fra-
meshift variant in MLKL, as well as an in-frame deletion of one
amino acid in the adjacent fatty acid 2-hydroxylase (FA2H)
gene38. The significant enrichment of an ultra-rare MLKL stop-
gain gene variant p.Q48X has been reported in Hong Kong
Chinese patients suffering from a form of Alzheimer’s disease39,
however more common germline MLKL gene variants are only
weakly associated with human disease in GWAS databases.
We have identified a single base pair germline mutation of
mouse Mlkl that encodes a missense substitution within the
MLKL brace region and confers constitutive activation indepen-
dent of upstream necroptotic stimuli. Given this mutant Mlkl
allele is subject to the same developmental and environmental
controls on gene expression as wild-type Mlkl, the postnatal
lethality in these mice provides insight into the physiological and
pathological consequences of dysregulated necroptosis. In paral-
lel, these findings inform the potential functional significance of
three common human MLKL polymorphisms that encode non-
conservative amino acid substitutions within, or in close proxi-
mity to, the brace helix that is mutated in the MlklD139V mouse.
Results
Generation of a constitutively active form of MLKL. Mpl−/−
mice, owing to genetic deletion of the major receptor for
thrombopoietin, have only 10% the wild-type number of per-
ipheral platelets. An ENU mutagenesis screen was performed to
identify mutations that ameliorate thrombocytopenia in Mpl−/−
mice via thrombopoietin independent platelet production40. A G1
founder, designated Plt15, had a modestly elevated platelet count
of 189 × 106 per mL compared with the mean forMpl−/− animals
(113 ± 57 × 106 per mL) and yielded 19 Mpl−/− progeny. Ten of
these mice had platelet counts over 200 × 106 per mL, consistent
with segregation of a dominantly acting mutation (Fig. 1a).
Linkage analysis and sequencing identified an A to T transversion
in Mlkl that was heterozygous in all mice with an elevated platelet
count (Fig. 1b). The MlklPlt15 mutation results in a non-
conservative aspartic acid-to-valine substitution at position
139 within the first brace helix. In the full-length mMLKL
structure, D139 forms a salt bridge with an arginine residue at
position 30 (α2 helix) of the MLKL four-helix bundle (4HB)
domain4 (Fig. 1c). This salt bridge represents one of a series of
electrostatic interactions between residues in helix α2 of the
MLKL 4HB domain and the two-helix ‘brace’ region. D139 of
mouse MLKL is conserved in all MLKL orthologues in vertebrata
reported to date (Fig. 1d). We have shown that the exogenous
expression of the 4HB domain of murine MLKL alone is suffi-
cient to kill mouse fibroblasts whereas exogenous expression of
full-length MLKL does not, suggesting an important role for this
‘electrostatic zipper’ in suppressing the killing activity of the
MLKL 4HB9. To determine if MLKLD139V exhibited altered
ability to induce necroptotic cell death relative to MLKLWT,
we stably expressed these full-length proteins under the control
of a doxycycline-inducible promoter in immortalized mouse
dermal fibroblasts (MDF) isolated from Wt, Mlkl−/−, Ripk3−/−
or Ripk3−/−;Casp8−/− mice. While expressed at comparable
levels, MLKLD139V induced markedly more death than MLKLWt,
on each of the genetic backgrounds tested (Fig. 1e–f, Supple-
mentary Fig. 1a), and formed a high molecular weight complex
observable by BN-PAGE in the absence of exogenous necroptotic
stimuli (Supplementary Fig. 1b). This indicates that MLKLD139V
is a constitutively active form of MLKL, capable of inducing
necroptotic cell death independent of upstream signaling and
phosphorylation by its activator RIPK3. Consistent with this
interpretation, exogenous expression of MLKLD139V in Ripk3−/−;
Casp8−/− MDFs was sufficient to induce the organelle swelling
and plasma membrane rupture characteristic of TNF-induced
necroptosis when examined by Transmission Electron Micro-
scopy (Fig. 1g).
MlklD139V causes a lethal perinatal inflammatory syndrome. To
define the phenotypic consequences of constitutively active MLKL
in the absence of any confounding effects resulting from Mpl-
deficiency, all subsequent studies were performed on a Mpl+/+
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Fig. 1 Murine MLKLD139V is a constitutively active form of MLKL. a Platelet counts from Mpl−/− mice (open circles, n= 80, 60) and offspring from
matings between Plt15 mice and Mpl−/− mice (closed orange circles, n= 19, 113) on a C57BL/6 or mixed C57BL/6:129/Sv background used for linkage
analysis (Mixed N2). b A missense mutation (D139V) in the second exon of Mlkl was identified in Plt15 mutant mice. DNA sequence shown for wild type
(top), a heterozygous mutant (middle), and a homozygous mutant (bottom). c Aspartate 139 contributes to an ‘electrostatic zipper’ joining brace helix 1
and the 4HB α2 helix of mouse MLKL (PDB code 4BTF)4. d Sequence logo of MLKL brace domain generated from multiple sequence alignment of all
Vertebrata MLKL sequences (257) available on OrthoDB. e Mouse dermal fibroblasts (MDFs) of indicated genotypes were stably transduced with MlklWt
and MlklD139V and expression induced with doxycycline (dox, white bars) or not induced (black bars) for 21 h. PI-positive cells were quantified by flow
cytometry. Means ± SEM are plotted for n= 4–8 experiments (a combination of biological repeats and independent experiments) for each genotype with
the exception of R3−/−C8−/−+MlklWt (n= 2, ±range). f Western blot analysis of whole cell lysates taken 6 h post doxycycline induction. g Transmission
electron micrographs of MDFs stimulated as indicated. Images selected for (f) and (g) are representative of 2–3 independent analyses with similar results.
TBZ; TNF+ Birinapant+ Z-VAD-fmk.
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background. Homozygous MlklD139V/D139V pups were born at
expected Mendelian frequencies (Supplementary Table 1) and were
ostensibly normal macroscopically and histologically at E19.5
(Supplementary Fig. 2a–d). However, by 3 days of age, although
outwardly indistinguishable from littermates (Fig. 2a), they
exhibited reduced body weight (Supplementary Fig. 2b) and failed
to thrive, with a maximum observed lifespan of 6 days under
conventional clean housing conditions. Like MlklWt/D139V mice,
Mlklnull/D139V compound heterozygotes were present at the expec-
ted frequency at P21 and developed normally to adulthood
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Fig. 2 Homozygous MlklD139V neonates exhibit dispersed upper body inflammation. a Macroscopic appearance of MlklWt/Wt, MlklWt/D139V and
MlklD139V/D139V mice at postnatal day 3. b Coronal section of mouth and neck region of postnatal day 2 litter mates stained with hematoxylin and eosin
(H&E). Dilated blood vessels and edema are indicated by arrows. c Serial mandible sections from postnatal day 3 litter mates stained with H&E and anti-
CD45. Inset black boxes are magnified in right panel. SL, sublingual gland. SM, submandibular gland. Images representative of n= 3–4 P3 pups per
genotype. d H&E stained sections from mediastinum of postnatal day 2 litter mates. Thymic cortical thinning and pericardial infiltration are indicated by
arrows. For full anatomical annotations for (b) and (d) see Supplementary Fig. 2h. (b) and (d) representative of n= 5–6 P2 pups examined with similar
characteristics. Scale bars for (b–d) range from 50 to 1000 μm as indicated. Multiplex measurement of plasma cytokine levels at E19.5 (e) and postnatal
day 3 (f). Each symbol represents one independent pup sampled;MlklWt/Wt – blue circles,MlklWt/D139V- red squares,MlklD139V/D139V- green triangles, with
bar height and error bars representing mean ± SD respectively for n= 3–to 19 pups as indicated. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.005 calculated using an
unpaired, two-tailed t-test.
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(Supplementary Table 2). Thus, the constitutive activity of
MLKLD139V was not affected by the presence of normal MLKL
protein suggesting it is the absolute allelic dose of MlklD139V that
determines perinatal lethality. To confirm that the phenotype of the
ENU derived MlklD139V mice was due to the MlklD139V missense
mutation, we independently generated MlklD139V mice using
CRISPR-Cas9 genomic editing. Homozygote CRISPR-MlklD139V/
D139V mice also died soon after birth (Supplementary Table 3).
Hematoxylin-Eosin stained-sections from both P2 and P3
MlklD139V/D139V pups revealed multifocal acute inflammation
characterized by neutrophilic infiltration, dilated blood vessels and
edema (Fig. 2b) in the dermis and subcutis of the head and neck.
These inflammatory features were not observed in MlklWt/Wt or
MlklWt/D139V littermates, nor in Mlkl−/− mice of the same age
(Supplementary Fig. 2i). Cells of hematopoietic origin, revealed
by immunohistochemical staining for CD45, were sparsely
distributed throughout the lower head and neck and confined
predominantly to a clearly delineated developing lymph node in
MlklWt/Wt and MlklWt/D139V littermates (Fig. 2c). In contrast,
CD45+ cells were more numerous and distributed throughout the
cutis, subcutis and salivary glands of MlklD139V/D139V pups
(Fig. 2c). A mixture of diffuse and focal inflammatory infiltration
was also observed within the mediastinum and pericardial space
of all P2/P3 MlklD139V/D139V pups examined, as was a paucity of
thymic cortical lymphocytes (Fig. 2d, Supplementary Fig. 2e),
phenotypes not evident in E19.5 embryos (Supplementary
Fig. 2d). No other consistent lesions were observed by
histopathology. Consistent with this inflammatory phenotype,
significantly elevated levels of several pro-inflammatory cytokines
and chemokines were evident in the plasma of both E19.5 and P3
MlklD139V/D139V pups (Fig. 2e, f). Blood glucose levels were
normal (Supplementary Fig. 2f, g).
Hematopoietic defects in MlklD139V mice. Although blood cell
numbers were unchanged in MlklD139V/D139V pups at E19.5
relative to MlklWt/Wt and MlklWt/D139V littermates, by
P3 significant deficits were evident in total white blood cell
count (due predominantly to reductions in lymphocyte num-
bers) and platelet numbers (Fig. 3a–c, Supplementary Fig. 3a).
Similarly, the numbers of hematopoietic stem and progenitor
cells were present at normal proportions in fetal livers of E18.5
MlklD139V/D139V pups, although increased levels of intracellular
ROS were uniformly evident in live cells, (Fig. 3d, e, Supple-
mentary Fig. 3b,c). By P2, deficits in CD150+CD48+ and CD150
+CD48− populations were present (Fig. 3f), accompanied by
increased AnnexinV binding in live cells (which indicates
phosphatidyl serine exposure) of all lineages (Fig. 3g). In adult
MlklWt/D139V mice, numbers of hematopoietic stem and pro-
genitor cells were unaffected (Fig. 3h); however, upon myelo-
suppressive irradiation, recovery of hematopoietic cell numbers
was delayed and characterized by increased expression of ROS
and Annexin V (Supplementary Fig. 3d, e). When challenged
with the cytotoxic drug 5-fluorouracil (5-FU), blood cell
recovery in MlklWt/D139V mice was similarly delayed (Fig. 3i). In
competitive transplants in which test MlklWt/D139V or MlklWt/Wt
marrow was co-injected with wild-type competitor marrow in
10:1 excess, as expected, MlklWt/Wt marrow contributed to 90%
of recipient blood cells 8 weeks after transplantation and
maintained that level of contribution for 6 months (Fig. 3j). In
contrast, MlklWt/D139V marrow performed poorly, contributing
to 25% and 51% of recipient blood cells at these times (Fig. 3j).
Similarly, while wild-type fetal liver cells contributed to the vast
majority of blood cells in irradiated recipients up to 6 months
after transplantation, cells from MlklD139V/D139V embryos failed
to compete effectively during this period (Fig. 3k). Heterozygote
MlklWt/D139V fetal liver cells contributed poorly in the first
month following the graft but recovered to contribute more after
six months (Fig. 3k). Thus, while tolerated under steady-state
conditions, heterozygosity of MlklD139V is deleterious under
conditions of hematopoietic stress. Bone marrow- derived HSCs
from MlklWt/D139V adults and fetal liver- derived HSCs from
MlklWt/D139V and MlklD139V/D139V pups also formed fewer and
smaller colonies in the spleens of lethally irradiated recipient
mice after 8 days (Supplementary Fig. 3f).
MlklD139V fibroblasts are less sensitive to necroptosis. To
examine if the constitutive activity of exogenously expressed
MLKLD139V results in an enhanced propensity for necroptosis in
cells that express MLKLD139V under the control of its endogenous
promoter, we immortalized MDFs from MlklWt/Wt, MlklWt/D139V
and MlklD139V/D139V littermates and from Mlkl−/− E19.5 pups.
We observed no significant differences in basal cell death levels,
nor any differences in the sensitivity of these cells to an apoptotic
stimulus such as TNF plus Smac mimetic (Fig. 4a, Supplementary
Fig. 4a). Surprisingly and in apparent contradiction to our initial
observations using exogenous expression systems, endogenous
expression of this Mlkl mutant revealed a significant and con-
sistent decrease in sensitivity to TNF-induced necroptosis
using three different pan-caspase inhibitors Q-VD-OPh, zVAD-
fmk and IDN-6556/emricasan in a MlklD139V dose-dependent
manner (Fig. 4a, Supplementary Fig. 4a). MDFs isolated from
MlklD139V/D139V homozygotes were up to 60% less sensitive to
TNF-induced necroptosis compared with MlklWt/Wt MDFs, but
were not as resistant as Mlkl−/− MDFs (Fig. 4a).
While there were no obvious differences in the levels of
MLKLWt and MLKLD139V protein following doxycycline induced
exogenous expression (Fig. 1f), MLKL was virtually undetectable
by Western blot in MlklD139V/D139V pup-derived fibroblasts
immortalized and cultured ex vivo (Fig. 4b). There was, however,
no significant reduction in Mlkl gene transcript levels in these
cells (Supplementary Fig. 4b) suggesting that this reduction was
post-transcriptional. A reduction in MLKLD139V protein levels
was also evident in whole E14.5 embryo protein lysates and in
single cell clones derived from HOXA9 factor dependent myeloid
cell lines derived from MlklD139V/D139V E14.5 embryos (Supple-
mentary Figs. 4c, j). Lysates from E14.5 embryos also clearly show
that MlklWt/D139V heterozygotes have intermediate levels of
MLKL, reflecting the intermediate sensitivity of MlklWt/D139V
MDFs to necroptotic stimuli (Supplementary Fig. 4c and Fig. 4a).
MLKLD139V protein turnover requires proteasome activity.
Measuring the half-life of endogenously expressed MLKLD139V is
not possible using conventional ‘pulse chase’ methods because
this mutant protein induces necroptotic cell death, so we capi-
talized on our previous observation that an N-terminally FLAG-
tagged MLKL 4HB forms a high molecular weight membrane-
associated complex just like the untagged form, but, unlike the
untagged version, does not kill cells9. Consistent with this
observation, N-FLAG full-length mouse MLKLD139V did not
induce cell death when inducibly expressed in Mlkl−/− MDFs
(Supplementary Fig. 4f).
Using this system, we were able to measure the cellular turn
over of MLKL by inducing N-FLAG-MLKLWT or N-FLAG-
MLKLD139V expression in Mlkl−/− MDFs for 15 h using
doxycycline then washing and culturing them in the absence of
doxycycline for a further 2–24 h. In the absence of a stimulus
(UT), the levels of N-FLAG-MLKLWT remained consistent over
the 24-h period (Fig. 4c), indicating that non-activated wild-type
MLKL is a stable protein in MDFs. However, when these cells
were treated with a necroptotic stimulus (TSI) to activate MLKL,
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the levels of wild-type MLKL rapidly declined even though these
cells were unable to undergo a necroptotic cell death. Consistent
with the fact that untagged MLKLD139V behaves as an auto-
activated form of MLKL (Fig. 1e), the half-life of N-FLAG-
MLKLD139V (4–6 h) was similar to the WT version stimulated
with TSI (Fig. 4c). Thus, the absence of endogenously expressed
MLKLD139V in E14.5 embryo lysates and cultured fibroblasts can
be attributed to the reduced post-translational stability of this
mutant auto-activated form of the protein.
To determine which cellular mechanism(s) are required for the
clearance of activated MLKLD139V, we included a series of
proteasome, lysosome and specific protease inhibitors during the
‘chase’ period after doxycycline was withdrawn (schematic in
Fig. 4d). The doses of all inhibitors were carefully titrated and
combined with pan-caspase inhibitor IDN6556 to minimize any
toxicity-associated apoptotic cell loss during the chase period. To
exclude any confounding RIPK3-mediated activation of the
necroptotic pathway by proteasome inhibitors41 (Supplementary
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Fig. 4f), the same experiment was also performed in Mlkl−/−,
RIPK3−/− MDFs (Supplementary Fig. 4d). Even at the very low
doses used, addition of the proteasome inhibitor PS341 was
accompanied by reduced clearance of N-FLAG-MLKLD139V and
the stabilization of higher molecular weight species that resemble
mono- and poly-ubiquitinated MLKL (Fig. 4d, Supplementary
Fig. 4d, i). This PS341 mediated protection of activated MLKL
was also evident when the same assay was performed for phospho
(p)S345-N-FLAG-MLKLWT (Supplementary Fig. 4e). The less
potent proteasome inhibitor MG132 did not stabilize MLKLD139V
to levels that could be resolved by western blotting of total MLKL
in this assay but did facilitate some stabilization of (p)-N-FLAG-
MLKLWT. Chloroquine, Bafilomycin and NH4Cl also partially
protected against (p)-N-FLAG-MLKLWT clearance, supporting
the potential role for lysosome mediated degradation of natively
phosphorylated MLKLWT15,17, but this was not observed for
constitutively activated N-FLAG-MLKLD139V using this approach
(Fig. 4d, Supplementary Fig. 4d).
Based on these findings we hypothesized that this MLKL-
clearance mechanism limits the capacity of MLKLD139V to kill
MlklWt/D139V and MlklD139V/D139V cells in culture and in vivo by
maintaining protein levels below a critical threshold. To test
whether this protective mechanism could be overwhelmed, we
incubated MDFs with agents that have been shown to induce
Mlkl expression (TNF, interferons (IFN) β and γ)42–44, or inhibit
its turnover (proteasome and lysosome inhibitors). MLKLD139V
protein in untreated MlklD139V/D139V MDFs was undetectable by
Western blot but became faintly detectable following addition of
these stimuli (Fig. 4b and Supplementary Fig. 4g). This correlates
with moderate but statistically significant increases in cell death
(particularly when compared with the lack of sensitivity to
conventional necroptotic stimuli (Fig. 4a)), when exposed to IFN-
β alone and in combination with proteasome or lysosome
inhibitors (Fig. 4e). A similar allele-dose dependent sensitivity is
also evident in primary MDFs (Supplementary Fig. 4h). To
examine if this mechanism may explain the reduced capacity of
MlklD139V/D139V fetal liver cells to reconstitute an irradiated host
(Fig. 2k), ex vivo colony forming assays were performed on fetal
liver cells derived from MlklWt/Wt and MlklD139V/D139V E14.5
littermates, alongside E14.5 livers taken from Mlkl−/− mice.
MlklD139V/D139V cells showed significantly increased sensitivity to
the inhibitory effects of IFN-β, with reduced colony formation at
low doses of cytokine that affectedMlklWt/Wt and Mlkl−/− colony
formation only marginally (Fig. 4f). Factor dependent myeloid
cells generated through HOXA9 immortalization of E14.5 liver
HSCs also demonstrated high rates of cell death under
conventional FDM culture conditions when derived from
MlklWt/D139V or MlklD139V/D139V embryos (Supplementary
Fig. 4k). Together, these experiments provide further evidence
for the existence of steady-state MLKL surveillance and turnover
mechanisms that suppress cell death by lowering the abundance
of activated MLKL below a killer threshold at the cellular
level6,14–16 and provide an in vivo precedent for both the
existence of this phenomenon and the lethal consequences of its
dysregulation in the form of the MlklD139V mouse.
To test whether the lethal inflammation in MlklD139V/D139V
neonates was mediated by the direct or indirect activation of the
inflammasome by active MLKL we crossed this line with the
Caspase 1/11 null mouse strain45–47. This did not enhance the
lifespan ofMlklD139V/D139V pups (Table 1). The combined genetic
deletion of Casp8 and Ripk3 did not rescue or extend the life of
MlklD139V/D139V mice, indicating that postnatal lethality is not
mediated by bystander extrinsic apoptotic cell death that may
occur secondary to initial waves of MLKLD139V-mediated
necroptosis (Table 1). The genetic deletion of Tnfr1, Myd88 or
Ifnar individually did not provide any extension to the lifespan of
MlklD139V homozygote pups (Table 1). These data indicate that
the removal of any one of these routes to NF-κB- and interferon-
mediated gene upregulation, inflammation or apoptotic cell death
is not sufficient to protect mouse pups against a double allelic
dose of MlklD139V.
Common human missense MLKL variants map to the brace
region. Given the severe inflammatory phenotype of murine
MlklD139V/D139V neonates and the significant defects in stress
hematopoiesis observed in murine MlklWt/D139V adults, we
explored the prevalence of brace region variation in human
MLKL. Examination of the gnomAD database48, which contains
human MLKL exome or genome sequence data from a total of
over 140,000 individuals revealed that the second and third
highest frequency human MLKL missense coding variants;
rs34515646 (R146Q) and rs35589326 (S132P), alter the same
brace helix (Table 2, Fig. 5a). The 4th most common human
MLKL polymorphism, rs144526386 (G202*V) is a missense
polymorphism identified exclusively in the context of a shorter
splice isoform of MLKL (*) named ‘MLKL2’49 (Table 2, Fig. 5b).
The full-length canonical transcript of MLKL encodes a 471
amino acid protein, while MLKL2 is an alternatively spliced
isoform of MLKL that is 263 amino acids long. MLKL2 lacks a
large portion of the pseudokinase domain which functions to
repress the killing potential of the 4HB domain6–9 and recruit co-
effectors like RIPK3 and HSP9013,50–52. Glycine202* is encoded
by an extension to exon 9 that is unique to the MLKL2 splice
isoform (Fig. 5a, b).
While the amino acid substitution MLKLR146Q is classified as
‘tolerated’ and ‘benign’ by SIFT/POLYPHEN 2 algorithms53,54
(Supplementary Table 1), R146 of human MLKL shows NMR
chemical shift perturbations in the presence of the negatively
Fig. 3 Alterations in hematopoietic cells and defective emergency hematopoiesis inMlklD139V mice. a–c Absolute white blood cell (WBCB), lymphocyte
and platelet numbers in peripheral blood of E19.5 and P3 pups, n= 6, 27, 44, 41, 10, and 11 as indicated. d Proportions of HSC (Lineage-Sca-1+c-kit+ (LSK)
CD150+ CD48−), MPP (LSK CD150− CD48−), HPC-1 (LSK CD150− CD48+) and HPC-2 (LSK CD150+ CD48+)82, n= 5 per genotype and (e) relative
levels of ROS (n= 4, 9, 5) (f) P2 bone marrow LSK populations (n= 9, 18, and 11) and (g) relative AnnexinV binding (n= 2, 11, 7). (h) HSC subtypes in
adult bone marrow, n= 9 per genotype. a–h Each symbol represents one independent animal; MlklWt/Wt – blue circles, MlklWt/D139V- red squares,
MlklD139V/D139V- green triangles, with bar height and error bars representing mean ± SD respectively, or range when n= 2. Red and white blood cells and
platelets in MlklWt/Wt (blue circles) and MlklWt/D139V (red squares) mice after treatment with 150mg per kg 5FU or saline. Means ± SEM from one
experiment in which three mice were sampled at each time point for each treatment group, similar results were obtained in an independent cohort. j Bone
marrow from MlklWt/Wt or MlklWt/D139V mice on CD45Ly5.2 background was mixed with wild-type CD45Ly5.1 competitor bone marrow and transplanted
into irradiated CD45Ly5.1/Ly5.2 recipients. Peripheral blood mononuclear cells (PBMCs) quantified after 56 and 180 days. Mean ± SEM are shown (3 donors
per genotype, 3–5 recipients per donor). k Fetal liver cells (CD45Ly5.2;MlklWt/Wt,MlklWt/D139V orMlkD139V/D139V) were transplanted into lethally irradiated
recipients (CD45Ly5.1/Ly5.2) together with competitor bone marrow (CD45Ly5.1). Contribution to PBMCs 28 days and 180 days after transplantation. Mean
± SEM are shown (2–10 donors per genotype, 2–6 recipients per donor). Host contribution (CD45Ly5.1/Ly5.2) is depicted in gray, competitor (CD45Ly5.1) in
white, and test (CD45Ly5.2) in black for (j) and (k). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.005 calculated using an unpaired, two-tailed t-test.
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Table 1 Postnatal lethality in MlklD139V/D139V homozygotes is independent of Tnfr1, Myd88, Ripk3, Casp8, Casp1, and Casp11.
Stage genotyped E14 E18 P21 P21 P21 P21 P21 P21 P21
C57BL/6 genetic background Wt Wt Wt Tnfr1−/− Myd88−/− Ripk3−/−, C8+/− Ripk3−/−, C8−/− Ifnar−/− C1−/−, C11−/−
MlklWt/Wt 58 (39) 7 (9) 15 (11) 19 (15) 3 (2) 10 (6) 2 (2) 15 (11) 10 (8)
MlklWt/D139V 70 (78) 17 (18) 30 (22) 41 (30) 6 (4) 14 (12) 5 (4) 30 (22) 21 (16)
MlklD139V/D139V 28 (39) 13 (9) 0 (11) 0 (15) 0 (2) 0 (6) 0 (2) 0 (11) 0 (8)
Total # genotyped 156 37 45 60 9 24 7 45 31
() - number of pups expected from Mendelian segregation, calculated from total number of pups genotyped and rounded to the nearest whole number. Gene names italicized.
E, embryonic day; P, days postnatal.
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Fig. 4 MLKLD139V undergoes constitutive post-translation turn-over.MDFs were isolated from MlklWt/Wt, MlklWt/D139V, MlkD139V/D139V or Mlkl−/− pups,
immortalized and stimulated as indicated for 21 h for quantification of PI-positive cells using flow cytometry (n= 4, 4, 4, and 6) (a), or for 4 h for western
blot analysis (b). Mlkl−/− MDFs were stably transduced with doxycycline-inducible FLAG-MLKLWT and FLAG-MLKLD139V constructs to examine MLKL
protein stability after doxycycline withdrawal (c) and in the presence of indicated compounds (FLAG-MLKLD139V) (d). e Immortalized MDFs from (a) were
stimulated as indicated for 21 h for quantification of PI-positive cells using flow cytometry (n= 2–3, 3–4, 4, 2–3). f E14.5 fetal liver cells from MlklWt/Wt,
MlkD139V/D139V or Mlkl−/− embryos were plated in the presence of indicated dose of IFN-β and colonies enumerated after 7 days (n= 4–6). (a, e and f)
represent mean ± SEM (A,E) or ±SD (f). b–e Representative images of at least three similar experiments. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.005 calculated
using an unpaired, two-tailed t-test.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16819-z
8 NATURE COMMUNICATIONS |         (2020) 11:3150 | https://doi.org/10.1038/s41467-020-16819-z | www.nature.com/naturecommunications
charged IP3 and IP6 phospholipid head groups, indicating a
possible role in membrane association and disruption11,55. Ser-
132 lies before the first structured residue of the first brace helix
in human MLKL (Fig. 5a)13,56,57. A Serine-to-Proline substitution
at this position is predicted to significantly impact the
conformation of the immediately adjacent W133 (brace helix)
and in turn, the proximal W109 within the 4HB domain
(Supplementary Fig. 5a). When mapped to a model of MLKL
splice-isoform 249 Glycine 202* is predicted to be on an isoform
2-specific helix and to form an interface along with S132 and
R146 of brace helix 1. While the precise structural consequence of
these three brace polymorphisms is unknown, modeling of
human MLKL predicts that disruption in the brace region favors
adoption of an activated conformation13. Consistent with this
prediction, the murine equivalent of the human S132P variant,
mMLKLS131P, formed high molecular weight membrane-
associated complexes and killed MDFs in the absence of a
necroptotic stimulus (Fig. 5c, d) when expressed at close to
endogenous levels (Supplementary Fig. 5b). Similarly to
mMLKLD139V, unstimulated mouse dermal fibroblasts generated
from the first generation of heterozygote and homozygote mutant
pups of a recently generated mMlklS131P CRISPR modified mouse
line demonstrated a clear reduction in MLKL protein levels
relative to those prepared from wild-type littermates (Supple-
mentary Fig. 5c), though the cellular clearance is not as complete
as observed for mMLKLD139V. Together, these data indicate that
constitutive activation and reduced protein stability is not a
unique, idiosyncratic feature of the mMLKLD139V, but also a
feature of a closely situated MLKL brace mutant, mMLKLS131P.
MLKL brace variants occur in trans more frequently in CRMO.
To investigate if human MLKL brace region polymorphisms play
a role in human autoinflammatory disease we examined their
frequency in cohorts suffering from ankylosing spondylitis (AS),
chronic recurrent multifocal osteomyelitis (CRMO), Guillain
Barré Syndrome (GBS) and Synovitis, Acne, Pustulosis, Hyper-
ostosis and Osteitis (SAPHO) Syndrome. The individual minor
allele frequencies of R146Q, S132P, and G*202V are not enriched
in these disease cohorts relative to healthy controls when popu-
lation distribution is accounted for (Supplementary Tables 4 and
5). However, these alleles occur in trans (making ‘compound
heterozygotes’—schematic in Fig. 5e) in 3 out of 128 CRMO
patients. This is 29 times the frequency that these combinations
are observed in healthy NIH 1000 genomes samples (where there
are only two compound heterozygotes for these polymorphisms
out of 2504 healthy individuals sequenced), or at 10–12 times the
frequency when only European CRMO patients and two separate
healthy European control populations were compared (Table 3).
Discussion
In contrast to apoptosis, necroptosis is widely considered to be an
inflammatory form of cell death. However, definitive evidence for
this proposition has yet to emerge. Because MLKL is activated by
inflammatory stimuli such as TNF it is very difficult to separate
cause from effect. The serendipitous identification of an auto-
activating mutant of MLKL (MlklD139V) in mice has allowed us to
explore the consequences of inappropriate necroptosis in the
absence of such confounding factors. Furthermore, it has led to
significant insights into the critical adult hematopoietic and
perinatal developmental processes that are most sensitive to
excessive MLKL activation, and into physiological mechanisms
that have evolved to neutralize activated MLKL.
In the absence of a robust immunohistochemical marker for
RIPK3-independent necroptosis, it is not possible to pinpoint
exactly which cell type/s undergo necroptosis in MlklD139V mice.
Nevertheless, the presence of high levels of circulating pro-
inflammatory cytokines in MlklD139V/D139V pups at E19.5 relative
to MlklWt/Wt and MlklWt/D139V littermates suggests that necrop-
tosis and ensuing inflammation begins in the sterile in utero
environment. This is not enough to overtly retard prenatal
development or affect hematopoietic cell populations. However,
upon birth and/or exposure to the outside environment the
capacity of homozygous MlklD139V/D139V pups to suppress
MLKLD139V activity is overwhelmed and they die within days of
birth. This is clearly a dose-dependent effect because both
MlklD139V/Wt and MlklD139V/null heterozygous mice are viable.
Postnatal death cannot be prevented by combined deficiencies in
Ripk3 and Casp8 nor by deficiency of other important inflam-
matory genes including Tnfr1, Myd88 or Ifnar. In light of the
elevated levels of circulating G-CSF, IL-6 and IL-5 observed, the
role of these key mediators in the initiation or potentiation of pre-
and perinatal inflammation in MlklD139V/D139V pups will be the
subject of future investigations.
The MlklD139V mutation was initially identified for its
capacity to moderately increase platelet production indepen-
dent of the thrombopoietin receptor Mpl. While the mechanism
underlying this observation remains unclear, it follows obser-
vations by others that another member of the necroptotic
pathway, RIPK3, plays a role in platelet activation58. The
reduced platelet levels observed in MlklD139V/D139V pups is
unlikely to be the sole cause of death given much more severe
thrombocytopenia is not lethal in Mpl−/− mice40. Difficulty
with suckling due to inflammatory infiltration of the head and
neck and resulting failure to thrive is one possible explanation
for the lethality in MlklD139V/D139V pups. However, the narrow
window of mortality for these pups and marked pericardial
immune infiltration make heart failure another potential cause
of sudden neonatal death.
Table 2 Human MLKL brace helix polymorphism frequency human MLKL SNP.
Feature R146Q – rs34515646 S132P – rs35589326 G202aV – rs144526386
CADD Score (phred-scaled) 0.407 6.381 3.825
UK Biobank – Total MAF (n) 0.0253 (487,658) 0.0161 (487,625) 0.0147 (487,488)
gnomAD – Total MAF (n) 0.0152 (141,339) 0.0138 (141,442) 0.01228 (141,400)
gnomAD – Highest MAF (n)
population
0.0252 (64,541) European (Non-Finnish) 0.0311 (5185) Ashkenazi Jewish 0.0245 (5184) Ashkenazi Jewish
1000 genomes – Total MAF (n) 0.0052 (2504) 0.0088 (2504) 0.0102 (2504)
1000 genomes – Highest MAF (n)
population
0.018 (503) European 0.024 (489) South Asian 0.021 (503) European
Gene names italicized.
N number of individuals sequenced, MAF Minor Allele Frequency – count.
aAlternative transcript.
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The MlklD139V mouse reveals that maintaining MLKL levels
below a threshold can prevent necroptotic activation. This strain
is a potential tool for the mechanistic and physiological exam-
ination of MLKL-mediated extracellular vesicle generation or
other cell death-independent roles related to inflammation that is
unconfounded by RIPK3 activation. While others have recently
shown that an ESCRT dependent repair or extracellular vesicle
extrusion can help protect membranes from limited MLKL
damage14–16, and that p-MLKL can be internalized and degraded
by the lysosome17 our data also suggest a role for the proteasome
in the disposal of activated MLKL, be it directly, or in its capacity
to generate free ubiquitin. This creates the possibility that these
mechanisms or the previously described ESCRT mechanisms
intersect in some way. Finally, the ability of these mechanisms to
hold single gene-dose levels of active MLKL in check without
deleterious consequences in vivo supports the idea that direct
inhibition of activated MLKL may be an effective means to
therapeutically prevent unwanted necroptotic cell death.
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Similarly, the MlklD139V mouse and assorted relevant crosses may
prove to be a useful tool for the further examination of whether
ROS production is co-incident with-, causative of- or con-
sequential to- necroptotic plasma membrane disruption in varied
tissue types and under highly physiologically relevant contexts
(recently reviewed by59).
While any mouse MLKL-human MLKL comparisons must be
made cautiously in light of the species-specific structural and
mechanistic differences5,12,13, it is notable that out of over
140,000 individuals surveyed, there is only one recorded case of a
human carrying a substitution equivalent to the mMlklD139V
mouse (hMLKLD140V; rs747627247) in the gnomAD database,
and this individual is heterozygous for this variant. To our sur-
prise, 3,841 individuals in gnomAD (55 of which are homo-
zygotes) carry a very closely situated MLKL brace region variant –
MLKLS132P. Our CRISPR-generated MlklS131P mouse equivalent
supports the connection between constitutive MLKL activation
and decreased MLKL protein stability. Preliminary observations
show that this variant manifests in a much milder and context
specific phenotype in mice than mMlklD139V, which is consistent
with its high frequency presence in the human population.
Overlaid with structural, biochemical, cell and animal-based
evidence of function, it is tempting to speculate that these human
MLKL brace region variants lead to altered MLKL function and/
or regulation in what is most likely a highly tissue-, context- or
even pathogen specific way60–62. While increased numbers and
examination of independent cohorts will be required to confirm
the statistical enrichment of human MLKL brace variants
occurring in trans in the autoinflammatory disease CRMO, this
patient cohort offers a tantalizing clue into their potential as
modifiers of complex, polygenic inflammatory disease in present
day humans.
Methods
Mice. All mice were backcrossed to C57BL/6 mice for >10 generations or generated
on a C57BL/6J background. Mlkl−/−, Tnfr1−/−, Myd88−/−, IFNAR1−/−, Ripk3−/−,
Casp8−/−, and Casp1/Casp11−/− mice were generated as described4,45,46,63–67.
Mice designated as E19.5 were obtained by Caesarean section from mothers that
received progesterone injections at E17.5 and E18.5. Independent mouse strains
that carry the D139V or S131P mutation in the Mlkl gene (MLKLD139V CRISPR)
were generated using CRISPR/Cas9 as previously described68. For D139V, one
sgRNA of the sequence GGAAGATCGACAGGATGCAG (10 ng per μL), an oligo
donor of the sequence ATTGGAATACCGTTTCAGATGTCAGCCAGCC
AGCATCCTGGCAGCAGGAAGATCGACAGGTTGCAGAAGAAGACGG
gtgagtctcccaaagactgggaaagagtaggccagggttgggggtagggtgg (10 ng per μL) and Cas9
mRNA (5 ng per μL) were injected into the cytosol of C57BL/6J zygotes. Mice were
sequenced across the mutated region to confirm incorporation of the altered codon
and analysis was performed after at least 2 back-crosses to C57BL/6. The same
procedure was followed for the generation of MLKLS131P CRISPR mice, using
sgRNA (CTGTCGATCTTCCTGCTGCC) and oligo donor (CTGTTGCTGC
TGCTTCAGGTTTATCATTGGAATACCGTTTCAGATGTCAGCCAGCCAG
CACCATGGCAGCAGGAAGATCGACAGGATGCAGAGGAAGACG
Ggtgagtctcccaaagactggga). Sex was not recorded for mice that were sampled at
E19.5, P2 and P3. Experiments using adult mice were performed with a combi-
nation of both males and females between 8 and 12 weeks of age. Mice were housed
in a temperature and humidity controlled specific pathogen free facility with a 12
h:12 h day night cycle. The WEHI Animal Ethics Committee approved all
experiments in accordance with the NHMRC Australian code for the care and use
of animals for scientific purposes.
Linkage analysis. We mapped the chromosomal location of the Plt15 mutation by
mating affected mice to 129/Sv Mpl−/− mice to produce N2 (backcross) and F2
(intercross) generations. A genome-wide scan using 20 N2 mice with the highest
platelet counts (287 ± 74 × 106 per mL, compared with 133 ± 75 × 106 per mL for
the overall population, Fig. 1a) localized the mutation to a region of chromosome 8
between D8Mit242 and D8Mit139 and linkage to this region was then refined.
Analysis of the F2 population revealed a significant reduction in the frequency of
mice homozygous for C57BL/6 alleles in this interval (e.g., D8Mit200 3/81 F2 mice
homozygous C57BL/6, p= 2.2 × 10−5 χ2-test), suggesting the Plt15 mutation
results in recessive lethality. The refined 2.01 Mb interval contained 31 annotated
genes, only five of which appeared to be expressed both in the hematopoietic
system and during embryogenesis (http://biogps.gnf.org/): Dead box proteins 19a
and 19b (Ddx19a and Ddx19b), Ring finger and WD repeat domain 3 (Rfwd3),
Mixed lineage kinase domain like (Mlkl), and WD40 repeat domain 59 (Wdr59).
Sequencing identified a single mutation, an A to T transversion in Mlkl that was
heterozygous in all mice with an elevated platelet count.
Reagents. Antibodies; Rat-anti mRIPK3 and rat anti-mMLKL 8F6 (selected for
affinity to residues 1–30 of mouse MLKL) and rat anti-MLKL 3H14 (MLKL brace
region) were produced in-house. Anti-Pro Caspase 8 (#4927) and GAPDH (#2113)
were purchased from Cell Signaling Technology. Anti-mouse MLKL pS345
Fig. 5 Three of the four highest frequency missense human MLKL SNPs encode non-conservative amino acid substitutions within or adjacent to the
brace helix region. a S132 and R146 (magenta) are located on either side of D140 (yellow—equivalent to mouse D139) in the first human MLKL brace
helix. Alternate amino acids encoded by human polymorphisms indicated in parentheses. b G202 is predicted to be on an α helix unique to MLKL2 isoform
and to form an interface along with S132 and R146. The mouse equivalent of human rs35589326 (hMLKLS132P), mMLKLS131P, spontaneously forms
membrane-associated high molecular weight complexes following Blue Native (BN) PAGE (c) and kills MDFs (d) in the absence of extrinsic necroptotic
stimuli when expressed in mouse dermal fibroblasts for 6 (c) and 21 hrs respectively (d). C; cytoplasmic fraction, M; crude membrane fraction, TSI; TNF,
Smac-mimetic and IDN6556, Chlor: Chloroquine. c Representative of two independent experiments with similar results. Error bars in (d) indicate the mean
± SEM of 4–5 independent experiments. e Schematic showing brace helix variant combinations identified as alleles in trans in three CRMO patients. fMTRs
are mapped onto the structure of MLKL to show regions that have low tolerance to missense variation in the human population (red) and regions that have
increased tolerance to missense variation (blue), normalized to the gene’s MTR distribution. g Multiple sequence alignment (MSA) conservation scores
are mapped onto the structure of MLKL to show regions that are highly conserved through evolution (red) and regions that are less conserved through
evolution (blue).
Table 3 Human MLKL brace helix compound heterozygotes in CRMO vs healthy controls.
Population Frequency of relevant
compound Hetsa in CRMO
Frequency of relevant
compound Hetsa in healthy
controls
CRMO:
Healthyb
2 tailed P value
(Fisher’s exact)
2 tailed P value (chi
square with Yate’s)
Globalc 0.023 (3/128) 0.0008 (2/2504) NIH 1KG 29:1 0.001 0.0001
Europeand 0.02 (2/101) 0.002 (1/503) NIH 1KG 10:1 0.074 0.1215
Europeand 0.02 (2/101) 0.0017 (25/14,542) QUT controls12:1 n/a 0.0022
aCombinations of R146Q – rs34515646, S132P – rs35589326 and G202*V – rs144526386 (Fig. 5e).
bFrequency ratio rounded to nearest whole number.
cCRMO patients and healthy controls of all ancestries included.
dCRMO patients and healthy controls of only European descent included.
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(ab196436) and anti-Actin (ab5694) were purchased from Abcam. Anti-VDAC
(AB10527) was purchased from Millipore. Fc-hTNF was produced in house and
used at a final concentration of 100 ng per mL. Recombinant mouse IFN-γ and β
were purchased from R&D Systems (Minneapolis, MN, USA) Q-VD-OPh and
zVAD-fmk were purchased from MP Biomedicals (Seven Hills, NSW, Australia).
Smac mimetic also known as Compound A, and the caspase inhibitor IDN-6556
were a gift from TetraLogic (Malvern, PA, USA). Propidium iodide, doxycycline,
and bafilomycin were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).
Cell line generation and culture. Primary mouse dermal fibroblasts were prepared
from skin taken from the head and body of E19.5 pups delivered by C-section or
from the tails of adult mice69. Primary MDFs were immortalized by stable lentiviral
transduction with SV40 large T antigen. Immortalized MDFs were stably trans-
duced with exogenous mouse MLKL cloned into the pFTRE 3 G vector, which was
generated by Toru Okamoto, and allows doxycycline- inducible expression as
described4. The following oligonucleotides were used for the assembly of
constructs;
mMlkl fwd; 5′-CGCGGATCCGCGCCACCatggataaattgggacagatcatcaag-3′,
mMlkl rev; 5′-CGGAATTCttacaccttcttgtccgtggattc-3′,
N-FLAG mMlkl fwd; 5′-CGCGGATCCAA gccacc atg gcg cgc cag gac-3′
N-FLAG mMlkl rev; 5′-CGCGGATCC tta cac ctt ctt gtc cgt gga ttc-3′
mMlkl D139V fwd; 5′-gaagatcgacaggTtgcagaggaagac-3′
mMlkl D139V rev; 5′-gtcttcctctgcaAcctgtcgatcttc-3′
mMlkl S131P fwd; 5′-gccagcctgcaCcctggcagcag-3′
mMlkl S131P rev; 5′-ctgctgccaggGtgcaggctggc-3′
Cells were maintained in culture as previously described44. 4-hydroxy-
tamoxifen regulated HOXA9 immortalised Factor Dependent Myeloid cells were
generated from mouse E14.5 fetal liver cells and cultured as described previously70.
Cell death assays. Flow Cytometry based cell death assays were performed using
5 × 104 MDFs per well in 24 or 48-well tissue culture plates4. Doxycycline (20 ng
per mL) was added together with death stimuli. Fc-hTNF was produced in house
and used at 100 ng per mL, Compound A Smac mimetic and IDN6556 were used at
500 nM and 5 μM respectively. zVAD-fmk and QVD-OPh were used at 25 and 10
μM respectively. Mouse and human interferons γ and β were used at 30 ng per mL,
PS341 and MG132 at 2 and 200 nM respectively and Bafilomycin at 300 nM. For
Incucyte automated imaging, MDFs were plated at a density of 8 × 103 cells per
well of a 96-well plate and permitted to attach for 3 h. FDMs were plated at a
density of 5 and 10 × 103 cells per well of a 48-well plate. 0.2 μg per mL propidium
iodide was in media alongside stimuli as indicated. Images were recorded at
intervals of 1 and 2 h using an IncuCyte S3 and numbers of PI positive cells per
mm2 at each time point quantified and plotted using IncuCyte S3 software.
MLKL turn-over assays. 5 × 104 MDFs per well were plated in 24-well tissue
culture plates and allowed to settle. Doxycycline (20 ng per mL) +/− TNF, Smac
Mimetic and IDN6556 was added. After 15 h, ‘no dox’ and ‘0’ wells were harvested.
Media was removed from remaining wells and cells were washed with PBS and
fresh media containing IDN6556 was re-added. Wells were then harvested 2, 4, 6,
8, and 24 h from this point. Cells were harvested by direct lysis in reducing SDS-
PAGE loading buffer.
MLKL protection assays. 5 × 104 MDFs per well were plated in 24-well tissue
culture plates and allowed to settle. Doxycycline (20 ng per mL) was added. After
18 hrs, ‘no dox’ and ‘T0’ samples were harvested. Media was removed and cells
washed before addition of fresh media containing TSI or IDN alone for 3 h. Cells
were washed again and media restored with IDN6556 alone (UT), or IDN6556+
inhibitor (MG132 (200 nM), PS341 (10–40 nM), Chloroquine (50 μM), Bafilomy-
cin (300 nM), Ca-074 Me (20 μM), TLCK (100 μM) and AEBSF (100 μM)) for a
further 21 h. Cells were harvested by direct lysis in reducing SDS-PAGE loading
buffer.
UBA pull downs. 2 × 106 MDFs stably transduced with doxycycline inducible N-
FLAG-mMLKLWT or N-FLAG-mMLKLD139V expressing constructs were seeded
and settled O/N before stimulation with 1 μg per mL doxycycline+/− TSI for
5 hrs. Cells were lysed in Urea-based UBA-pull down buffer, ubiquitylated proteins
enriched and Usp21-treated as described previously71.
Transmission electron microscopy. Murine dermal fibroblasts prepared from
mice of the indicated genotypes were untreated or stimulated with the indicated
agents for the indicated hours. Then, cells were fixed with 2% glutaraldehyde in 0.1
M phosphate buffer, pH 7.4, postfixed with 2% OsO4, dehydrated in ethanol, and
embedded in Epok 812 (Okenshoji Co.). Ultrathin sections were cut with an
ultramicrotome (ultracut N or UC6: Leica), stained with uranyl acetate and lead
citrate, and examined with a JEOL JEM-1400 electron microscope. The viability of
a portion of these cells was determined by measuring LDH release as described
previously72.
Mouse histopathology. Caesarian-sectioned E19.5 and Day P2/3 pups were
euthanized by decapitation and fixed in 10% buffered formalin. Five-micrometers
coronal sections were taken at 200-μm intervals for the full thickness of the head, 5-
μm sagittal sections were taken at 300-μm intervals for the full thickness of the
body. A thorough examination of these sections was performed by histopatholo-
gists Aira Nuguid and Tina Cardamome at the Australian Phenomics Network,
Melbourne. Findings were confirmed by Veterinary Pathologist Prof. John W.
Finney, SA Pathology, Adelaide and clinical Pathologist Prof. Catriona McLean,
Alfred Hospital, Melbourne.
Measurement of relative thymic cortical thickness. Representative images of
thymus sections were analysed to determine relative cortical thickness using
ImageJ. Briefly, medullary areas were identified on the basis of H and E staining
and removed from the larger thymus structure using the Image J Image Calculator
function to isolate the cortical region. The thickness of the cortical region, defined
by the radius of the largest disk that can fit at a pixel position, was determined
using the Local Thickness plugin in ImageJ (http://www.optinav.info/
Local_Thickness.htm).
Immunohistochemistry. Following terminal blood collection, P0 and P3 pups
were fixed for at least 24 h in 10% buffered formalin and paraffin embedded before
microtomy. Immunohistochemical detection of cleaved caspase 3 (Cell Signaling
Technology #9661) and CD45 (BD) was performed as described previously23.
Cytokine quantification. All plasma was stored at −80 °C prior to cytokine ana-
lyses. Cytokines were measured by Bioplex Pro mouse cytokine 23-plex assay (Bio-
Rad #M60009RDPD) according to manufacturer’s instructions. When samples
were designated ‘<OOR’ (below reference range) for a particular cytokine, they
were assigned the lowest value recorded for that cohort (as opposed to complete
exclusion or inclusion as ‘zero’ which would artificially inflate or conflate group
averages respectively). Values are plotted as fold change relative to the mean value
for the Wt/Wt samples, and p values were calculated in Microsoft Excel using a
two-tailed TTEST, assuming unequal variance. Data is only shown for cytokines
that displayed statistically significant differences between genotypes at either of or
both day E19.5 and day P3.
Hematological analysis. Blood was collected from P0 and P3 pups into EDTA
coated tubes using heparinized glass capillary tubes from the neck cavity imme-
diately after decapitation. After centrifugation at 500 G for 5 min, 5–15 μL of
plasma was carefully removed and this volume was replaced with PBS. Blood cells
were resuspended and diluted between 8–20-fold in DPBS for automated blood cell
quantification using an ADVIA 2120 hematological analyzer within 6 h of harvest.
Blood was collected from adult mice retro-orbitally into tubes containing EDTA
and analyzed using an ADVIA120 automated hematological analyzer (Bayer).
Transplantation studies. Donor bone marrow or fetal liver cells were injected
intravenously into recipient C57BL/6-CD45Ly5.1/Ly5.2 mice following 11 Gy of
gamma-irradiation split over two equal doses. Recipient mice received neomycin
(2 mg per mL) in the drinking water for 4 weeks. Long term capacity of stem cells
was assessed by flow cytometric analysis of donor contribution to recipient mouse
peripheral blood and/or hematological organs up to 6 months following engraft-
ment. Recovery from cytotoxic insult was assessed by automated peripheral blood
analysis at regular times following treatment of mice with 150 mg per kg 5-
fluorouracil (5-FU).
Flow cytometry. To analyze the contribution of donor and competitor cells in
transplanted recipients, blood cells were incubated with a combination of the
following antibodies: Ly5.1-PE, Ly5.2-FITC, Ly5.2-biotin or Ly5.2 PerCPCy5.5
(antibodies from Becton Dickenson, Ca). If necessary, cells were incubated with a
streptavidin PECy5.5 (BD), mixed with propidium iodide (Sigma) and analysed on
a LSRI (BD Biosciences) flow cytometer. To analyse the stem- and progenitor cell
compartment, bone marrow cells were incubated with biotinylated or Alexa700
conjugated antibodies against the lineage markers CD2, CD3, CD4, CD8, CD34,
B220, CD19, Gr-1, and Ter-119. For stem and progenitor cell detection antibodies
against cKit, Sca-1, CD48, AnnexinV, CD105, FcγRII/III or CD135 in different
combinations (see antibody list for details). Finally FluoroGold (AAT Bioquest
Cat#17514) was added for dead cell detection. Cells were then analysed on LSRII or
Fortessa1 (BD Biosciences) flow cytometers.
Reactive oxygen species (ROS) detection. ROS was detected by using
Chloromethyl-H2DCFDA dye according to the manufacturer’s instructions (Invi-
trogen Cat#C6827). In brief, bone marrow cells were loaded with 1 μM
Chloromethyl-H2DCFDA for 30 min at 37 °C. Loading buffer was then removed,
and cells were placed into 37 °C StemPro-34 serum free medium (ThermoFisher
Cat#10639011) for a 15-min chase period. After incubation cells were placed on ice
and stained with surface antibodies suitable for FACS analysis. Cells were analysed
using a LSRII flow cytometer (Becton Dickinson).
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E14.5 fetal liver colony forming assays. 1 × 104 fetal liver cells were plated as 1
mL cultures in 35 mm Petri dishes in DMEM containing 10% FCS, 0.3% agar and
104 U per mL GM-CSF. IFN-β was added to the cultures in increasing con-
centrations from 0 to 30 ng per mL. Colony formation was scored after 7 days of
incubation at 37 °C, fully humidified with 10% CO2.
Quantitative PCR. RNA was prepared using Trizol (Invitrogen) according to the
manufacturer’s instructions and 10 μg was used for first strand cDNA synthesis
using SuperScript II (Life Technologies). 0.5 μg of cDNA was then used in a
TaqMan PCR reaction with Universal PCR mastermix and murine Mlkl
(Mm1244222_n1) and GAPDH (Mm99999915_m1) Taqman probes (Thermo-
Fisher) on an ABI 7900 Fast Real-Time PCR instrument (Applied Biosystems).
Mlkl expression relative to GAPDH control was determined using SDS version 2.3
program (Applied Biosystems) and expressed as ΔCT values.
Statistics (mouse and cell-based assays). Please consult figure legends for
description of error bars used. All data points signify independent experimental
repeats, and/or biologically independent repeats. All p values were calculated in
Microsoft Excel or Prism using an unpaired, two-tailed t-test, assuming unequal
variance and not adjusted for multiple comparison. Asterices signify that p ≤ 0.05
(*), p ≤ 0.01(**) or p ≤ 0.005 (***). All comparisons were made between MlkWt/Wt
and MlkD139V/D139V groups only (with the exception of data derived from adult
mice, which were comparisons between MlkWt/Wt and MlkWt/D139V groups only.
Whole-exome sequencing. DNA from CRMO probands and their family mem-
bers (when available) was purified from saliva or blood and prepared for whole-
exome sequencing (WES). The samples underwent WES at several different times,
enriched using the Agilent SureSelect Human All Exon V4, V5 or V6+UTR
(Agilent Technologies) before sequencing at either Otogenetics, Inc (Atlanta, GA),
Beckman Coulter Genomics (Danvers, MA), or at the University of Iowa Genomics
Core (Iowa City, IA). The fastq files were quality-checked and processed to vcf
format as described73. Variants for all samples were called together using GATK’s
Haplotype Caller74 and were recalibrated and hard-filtered in GATK as descri-
bed73. Variants were annotated with minor allele frequencies (MAFs) from 1000
genomes75, ExAC and gnomAD48 and with information regarding the effect of
each variant using SNPSift/SNPEff76. The databases used for annotation were
dbNSFP2.977 (for MAFs) and GRCh37.75 for protein effect prediction.
Ancestry determination. Ancestry was determined for each CRMO proband
using the LASER software package78. A vcf file including ten probands at a time
was uploaded to the LASER server and the TRACE analysis was selected using the
Worldwide panel. For probands with indeterminate ancestry using the Worldwide
panel, the European and Asian panels were used. Principal component values for
each proband were plotted using R Statistical Software and the code provided in the
LASER package.
MLKL variant quantification. 1000 Genomes: Vcf files from 1000 genomes were
annotated and filtered as described previously79. Values for MLKL variants
rs35589326 (S132P), rs34515646 (R146Q), and rs144526386 (G202V) as well as all
MLKL coding variants were queried and tabulated for allele and genotype count for
participants of all ancestry (n= 2504), and for those of European ancestry (n=
503). Compound heterozygous variants were evident due to the phasing of all
variants in the 1000 genomes dataset. CRMO: Allele and genotype counts for all
MLKL coding variants were tabulated in probands of European ancestry (n= 101)
and for all probands (n= 128). Compound heterozygous variants were identified
using parental sequence data. AS: DNA from all subjects in AS cohort were gen-
otyped using the Illumina CoreExome chip following standard protocols at the
Australian Translational Genomics Centre, Princess Alexandra Hospital, Brisbane.
Bead intensity data was processed and normalized for each sample and genotypes
called using the Illumina Genome Studio software. All the samples listed in the
table have passed quality control process80. GB: Genotyping was performed in an
ISO15189-accredited clinical genomics facility, Australian Translational Genomics
Centre (ATGC), Queensland University of Technology. All samples were geno-
typed by Illumina HumanOmniExpress (OmniExpress) BeadChip81. QUT con-
trols: A collection of healthy control data of verified European ancestry from
various cohort studies, complied by the Translational Genomics Group, QUT and
typed on an Illumina CoreExome microarray. Includes data from The UK
Household Longitudinal Study, led by the Institute for Social and Economic
Research at the University of Essex and funded by the Economic and Social
Research Council. The survey was conducted by NatCen and the genome-wide
scan data were analysed and deposited by the Wellcome Trust Sanger Institute.
University of Essex. Institute for Social and Economic Research, N. S. R., Kantar
Public. Understanding Society: Waves 1–8, 2009–2017 and Harmonised BHPS:
Waves 1–18, 1991–2009. [data collection]. 11th Edition. UK Data Service., (2018).
Patient recruitment. All genomic data was derived from patients recruited with
consent as described previously48,80,81, and with the approval of human ethics
review boards of all Institutes that participated in human genetics studies;
University of Iowa Carver College of Medicine, Queensland University of Tech-
nology, Australian National University, Shanghai Renji Hospital, JiaoTong Uni-
versity of Shanghai, The Hospital for Sick Children and the University of
Toronto, University of Sydney, Australian Institute of Sport, University of Freiburg,
Princess Alexandra Hospital, Memorial Hermann Texas Medical Centre, The
University of Queensland, Oregon Health and Science University), Groupe Fran-
çaise d’Etude Génétique des Spondylarthrites (GFEGS) and the University of
Oxford.
Statistical analysis (human data). Statistical comparisons were performed at the
level of allele frequency or the level of compound heterozygote sample frequency
using either a Fisher’s exact test or a Chi-Squared test with Yates correction as
specified under each table. Compound heterozygous variants were quantified and
compared at the individual rather than the allelic level, where individuals with and
without qualifying variants were compared at the allelic level.
Web resources. gnomAD – https://gnomad.broadinstitute.org/
http://asia.ensembl.org
OrthoDB - https://www.orthodb.org
CADD - https://cadd.gs.washington.edu/
Clustal Omega - https://www.ebi.ac.uk/Tools/msa/clustalo/
WEBLOGO - https://weblogo.berkeley.edu/logo.cgi
Missense Tolerance Ratio (MTR) Gene Viewer - http://biosig.unimelb.edu.au/
mtr-viewer
UK biobank - https://www.ukbiobank.ac.uk
Understanding Society - https://www.understandingsociety.ac.uk/
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The biological tools generated for MLKL during this study are available from the
corresponding authors on reasonable request. MLKL gene variants in CRMO can be
accessed from Harvard Dataverse, V1 [https://doi.org/10.7910/DVN/BL3SXQ]. The
source data underlying Figs. 1a, d, e–g, 2a–f, 3a–k, 4a–f, 5c, d and Supplementary
Figs. 1a, b, 2a–h, 3a, c, d–f, 4b, d–j are provided as a Source Data file. Source data are
provided with this paper.
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